All Stories

  1. What's new with tics and Tourette's? Highlights from 2023.
  2. Tics that started recently usually get better but almost never go away completely.
  3. Tics in ADHD
  4. Tourette syndrome research highlights from 2022
  5. Door-To-Door Video-Enhanced Prevalence Study of Tourette Disorder Among African Americans
  6. Smoke gets in your tics
  7. Study protocol: A cross-sectional survey of clinicians to identify barriers to clinical practice guideline implementation in the assessment and treatment of persistent tic disorders
  8. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
  9. Early‐Life and Family Risk Factors for Tic Disorder Persistence into Adulthood
  10. Tics in ADHD
  11. Finding reviewer suggestions for multi-author papers
  12. Functional tic-like presentations differ strikingly from Provisional Tic Disorder
  13. Editorial: Recent advances in understanding Tourette syndrome, tic disorders and functional tics
  14. Smoke gets in your tics
  15. Will people buzz their wrist in their daily life to help their tics?
  16. Testing whether median nerve stimulation helps tics by the mechanism we thought it did
  17. Tics in ADHD
  18. Suggestions for new NIH grant applicants
  19. Peripheral nerve induction of inhibitory brain circuits to treat Tourette syndrome: A randomized crossover trial
  20. Functional tic-like presentations differ strikingly from Provisional Tic Disorder
  21. TikTok Tourette’s: Are We Witnessing a Rise in Functional Tic-Like Behavior Driven by Adolescent Social Media Use?
  22. Tic prevalence by direct observation in an elementary school
  23. Tourette syndrome research highlights from 2021
  24. Diagnosis and Management of Functional Tic-Like Phenomena
  25. Door-to-door Video-Enhanced Prevalence Study of Tourette Disorder Among African Americans
  26. Why Tic Severity Changes from Then to Now and from Here to There
  27. 3.122 Open Trial of Median Nerve Stimulation for the Treatment of Tourette’s Disorder
  28. 13.2 Predictors of Tic Symptom Evolution After First Onset
  29. Functional tic-like presentations differ strikingly from Provisional Tic Disorder
  30. Median nerve stimulation for treatment of tics: A 4-week, open trial with ecological momentary assessment
  31. TikTok Tourette's: are we witnessing a rise in neurological conditions driven by adolescent social media use?
  32. Why tic severity changes from then to now and from here to there
  33. The start of the biggest brain imaging and genetics study ever in Tourette syndrome
  34. Finding reviewer suggestions for multi-author papers
  35. Optimal timing for lithium levels
  36. Tourette syndrome research highlights from 2021
  37. Tourette syndrome research highlights from 2020
  38. Neurobiology and Functional Anatomy of Tic Disorders
  39. The timing of tics is fractal, even in the first few months of a tic disorder
  40. Tourette syndrome research highlights from 2020
  41. Treatment failure in persistent tic disorders: an expert clinicians’ consensus-based definition
  42. Predicting Clinical Course from Subcortical Shape in Provisional Tic Disorder
  43. Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
  44. Recent progress on Tourette syndrome
  45. A Comprehensive Review of Tic Disorders in Children
  46. What happens to tic disorders over time?
  47. "I can hold my tics back for a while. What does that tell me?"
  48. TicTimer Web: software for measuring tic suppression remotely
  49. Electronic medical records need to accommodate confidentiality for presymptomatic testing
  50. The Child with Tics or Other Common Movement Disorders
  51. Tourette syndrome research highlights from 2019
  52. Course of tic disorders over the lifespan
  53. Tourette syndrome research highlights from 2019
  54. TicTimer Web: software for measuring tic suppression remotely
  55. Correlates and clinical implications of tic suppressibility
  56. Size of hippocampus predicts improvement in children with recent-onset tics
  57. Phonic tics and one motor tic? Call it Tourette syndrome.
  58. Can we measure Parkinson disease severity with levodopa and MRI?
  59. Age-dependent differences in functional brain networks are atypical in Tourette syndrome
  60. In obesity, pictures of high-calorie food elicit dopamine release equally when hungry or full.
  61. Hippocampal volume in Provisional Tic Disorder predicts tic severity at 12-month follow-up
  62. What happens to children with recent-onset tics, and why?
  63. Dopamine buffering capacity imaging: A pharmacodynamic fMRI method for staging Parkinson disease
  64. 2.54 EXPLORING BEHAVIORAL MARKERS PREDICTING ONE-YEAR TIC OUTCOME IN CHILDREN WITH RECENT-ONSET TICS
  65. Treating depression in epilepsy: a controlled trial
  66. The urge to blink in Tourette syndrome
  67. Tourette syndrome research highlights from 2018
  68. Atypical Functional Connectivity In Tourette Syndrome differs between Children and Adults
  69. Tic Suppression in Children With Recent-Onset Tics Predicts 1-Year Tic Outcome
  70. In Provisional Tic Disorder, better tic suppression predicts better prognosis
  71. Provisional Tic Disorder is not so transient
  72. Correction: Brain structure in pediatric Tourette syndrome
  73. Ziprasidone may have a role in treating psychosis in Parkinsonian disease
  74. The urge to blink in Tourette syndrome
  75. How to switch to pimavanserin from an older antipsychotic for psychosis in Parkinson's disease
  76. Atypical Functional Connectivity in Tourette Syndrome Differs Between Children and Adults
  77. Transient tics aren't: Outcome of recent-onset tic disorder at one year
  78. Testing a new (D1) dopamine blocking strategy to treat Tourette syndrome in children
  79. TicTrainer software
  80. Research on tic disorders from 2017
  81. Effects of DBS in dorsal vs. ventral STN
  82. Who can suppress tics best?
  83. Tourette Syndrome
  84. TicTimer software for measuring tic suppression
  85. TicTrainer web software for tic suppression training
  86. Tourette syndrome research highlights from 2016
  87. Patterns and predictors of tic suppressibility in youth with tic disorders
  88. 4.36 A Randomized, Double-Blind, Placebo-Controlled Study of the D1 Receptor Antagonist Ecopipam for Children and Adolescents With Tourette's Disorder
  89. TicTimer: software for measuring tic suppression
  90. Tourette syndrome research highlights from 2016
  91. Mapping movement, mood, motivation, and mentation in the subthalamic nucleus
  92. A Case of Apparent Upper-Body Freezing in Parkinsonism while Using a Wheelchair
  93. What creates the urge to tic in Tourette syndrome?
  94. Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia
  95. Brain structure in pediatric Tourette syndrome
  96. VISIT-TS: A multimedia tool for population studies on tic disorders
  97. A picture is worth 1000 words: a new tool for Tourette studies
  98. Tourette syndrome research highlights 2015
  99. Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status
  100. Sweet Dopamine: Sucrose Preferences Relate Differentially to Striatal D 2 Receptor Binding and Age in Obesity
  101. Brain structure in pediatric Tourette syndrome
  102. When do tics turn into Tourette syndrome?
  103. Return of QuanDyn(TM)
  104. Designing MRI studies of children with neuropsychiatric disorders
  105. Machine learning "diagnosis" of Tourette syndrome by resting brain activity
  106. Correction: Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity
  107. Safety of i.v. L-DOPA
  108. Automated training to hold still
  109. A review session can raise medical student scores on the psychiatry shelf exam
  110. Impact of a structured review session on medical student psychiatry subject examination performance
  111. Stand up for i.v. levodopa!
  112. Brain imaging in Tourette's, 2014-2015
  113. Safety of i.v. L-DOPA (preprint)
  114. Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity
  115. Tourette Syndrome research highlights 2014
  116. Brain dopamine pathways influence emotional eating
  117. Rapid quantitative pharmacodynamic imaging with Bayesian estimation
  118. Whole-brain blood flow correction in ASL
  119. Tourette Syndrome research highlights 2014
  120. Kids can suppress tics early on--if the price is right
  121. Levodopa effects on [11C]raclopride binding in the resting human brain
  122. Tics
  123. Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI
  124. F1000Research: Tics welcomes you to 21st century biomedical publishing
  125. Intro to special issue on Tourette syndrome
  126. Current anxiety disorder affects mood response to STN DBS in PD
  127. A revised method for measuring distraction by tactile stimulation
  128. Anatomical location in STN matters for DBS in Parkinson's
  129. Insulin, dopamine D2 receptors, and monetary reward discounting: A common pathway for food and drug addiction
  130. Developmental Changes in the Organization of Functional Connections between the Basal Ganglia and Cerebral Cortex
  131. Spatial Reorganization of Putaminal Dopamine D2-Like Receptors in Cranial and Hand Dystonia
  132. Levodopa-stimulated dopamine release in Tourette syndrome
  133. A within-subject comparison of seizure duration with etomidate and methohexital in electroconvulsive therapy
  134. Prolactin and fMRI response to SKF38393 in the baboon
  135. Automatic size and shape measurements of deep brain structures in Tourette syndrome
  136. Rapid quantitative pharmacodynamic imaging by a novel method: theory, simulation testing and proof of principle
  137. Towards objectively quantifying sensory hypersensitivity: a pilot study of the “Ariana effect”
  138. Olanzapine for psychosis in Parkinson disease
  139. Neurobiology and Functional Anatomy of Tic Disorders
  140. A comparison of D2 receptor specific binding in obese and normal‐weight individuals using PET with (N‐[11C]methyl)benperidol
  141. NMB PET outside the striatum
  142. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
  143. Mood Response to Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
  144. Prospectively Determined Impact of Type 1 Diabetes on Brain Volume During Development
  145. A New (Old) Treatment Option for Depression in Parkinson's Disease
  146. Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours
  147. Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol) (TSfMRI)
  148. A Perfusion MRI Study of Emotional Valence and Arousal in Parkinson’s Disease
  149. Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
  150. Tics
  151. Deep brain stimulation for Tourette syndrome
  152. Hippocampal Volumes in Youth With Type 1 Diabetes
  153. Neuroimaging in Baboons
  154. Cerebral Mitochondrial Metabolism in Early Parkinson's Disease
  155. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease
  156. Psychiatric screening for DBS
  157. The Cognitive Correlates of Functional Status: A Review From the Committee on Research of the American Neuropsychiatric Association
  158. Regional Brain Volume Differences Associated With Hyperglycemia and Severe Hypoglycemia in Youth With Type 1 Diabetes
  159. Validity of large-deformation high dimensional brain mapping of the basal ganglia in adults with Tourette syndrome
  160. Intravenous levodopa administration in humans based on a two-compartment kinetic model
  161. The Value of Quantitative Electroencephalography in Clinical Psychiatry: A Report by the Committee on Research of the American Neuropsychiatric Association
  162. Repetitive and impulsive behaviors in treated Parkinson disease
  163. II.P5 Effects of Parkinson Disease (PD) laterality on spatial working memory performance
  164. Sex, Lies, and Neuroimaging
  165. Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group
  166. Brain Stimulation in Psychiatric Treatment
  167. Blood Flow Imaging of the Brain: 50 Years Experience
  168. Levodopa Challenge Neuroimaging of Levodopa-Related Mood Fluctuations in Parkinson's Disease
  169. Pathophysiology of parkinsonism due to hydrocephalus
  170. Dopaminergic modulation of response inhibition: an fMRI study
  171. Cognitive-pharmacologic functional magnetic resonance imaging in tourette syndrome: a pilot study
  172. Atlas Template Images for Nonhuman Primate Neuroimaging: Baboon and Macaque
  173. Asymmetric regional cerebral blood flow in sedated baboons measured by positron emission tomography (PET)
  174. Rapid intravenous loading of levodopa for human research: clinical results
  175. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease
  176. A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist
  177. Psychiatric Neuroimaging Research
  178. Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease
  179. Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease
  180. Template Images for Nonhuman Primate Neuroimaging: 2. Macaque
  181. Template Images for Nonhuman Primate Neuroimaging: 1. Baboon
  182. Dopa-Induced Blood Flow Responses in Nonhuman Primates
  183. Response to levodopa challenge in Tourette syndrome
  184. Neuropsychiatry of movement disorders
  185. On the efficiency of stereologic volumetry as commonly implemented for three-dimensional digital images
  186. Diminished regional cerebral blood flow response to vibration in patients with blepharospasm
  187. Altered thalamic response to levodopa in Parkinson’s patients with dopa-induced dyskinesias
  188. Putamen volume in idiopathic focal dystonia
  189. Preventing contractures in NMS and dystonia
  190. MPTP induces dystonia and parkinsonism
  191. Baboon Basal Ganglia Stereotaxy Using Internal MRI Landmarks: Validation and Application to PET Imaging
  192. Personality disorder scores improve with effective pharmacotherapy of depression
  193. Stereological MRI volumetry of the frontal lobe
  194. A Metric for Testing the Accuracy of Cross-Modality Image Registration: Validation and Application
  195. The Dexamethasone Suppression Test for Diagnosing Depression in Stroke Patients
  196. Anosognosia for Depressive Signs
  197. Diagnosing Depression After Stroke
  198. Platelet Binding Characteristics Distinguish Placebo Responders from Nonresponders in Depression
  199. MRI volumetry of prefrontal cortex
  200. Hippocampal MR volumetry
  201. Severe Imipramine-Induced Myoclonus in a Patient with Psychotic Bipolar Depression, Catatonia, and Schizencephaly
  202. Subcortical brain anatomy in anorexia and bulimia
  203. Faculty of 1000 evaluation for Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome.
  204. TicTimer software for measuring tic suppression
  205. “But my department chair wants big-name journals”: Gentle steps to open publishing
  206. Software for web-based tic suppression training
  207. Tics
  208. Treatment of Parkinson’s disease psychosis
  209. Tourette syndrome research highlights from 2016
  210. BillCorrectly: A software tool to help psychiatrists bill E&M codes appropriately
  211. Suggestions for new NIH grant applicants